Search Results
401 results
Your search is now limited to «Eli Lilly» expert search.
Zacks.com 03/22/2019 17:50
In the latest trading session, Eli Lilly ( LLY - Free Report) closed at $128.30, marking a -0.01% move from the previous day.
More from Zacks.com:
NASDAQ 03/21/2019 22:07
Lilly, though, has clearly demonstrated that it's up to the task with a spate of high-value drug approvals since 2014.
More from NASDAQ:
24/7 Wall Street 03/20/2019 08:55
Eli Lilly and Co. (NYSE: LLY) was started with a Buy rating and assigned a $140 price target (versus a $126.59 close) at UBS.
More from 24/7 Wall Street:
PR Newswire 03/20/2019 08:45
PLYMOUTH MEETING, Pa. and INDIANAPOLIS, March 20, 2019 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) and Eli Lilly and Company (NYSE: LLY) today announced six projects that aim to improve the delivery of gastric and gastroesophageal...
More from PR Newswire:
FierceMedicalDevices 03/20/2019 07:53
As Merck boosts R&D pact, NGM Bio gains Genentech, Lilly veteran as new R&D chief.
More from FierceMedicalDevices:
Becker's Hospital Review 03/19/2019 11:59
Eli Lilly has pledged to spend $91 million renovating its Lilly Technology Center in the city.
More from Becker's Hospital Review:
FiercePharmaManufacturing 03/19/2019 09:10
Despite objections from some local lawmakers, the Indianapolis City-County Council approved a $7 million abatement for Eli Lilly's $91 million expansion project, the Indianapolis Business Journal reports.
More from FiercePharmaManufacturing:
WN.com 03/17/2019 07:14
When Erin Gilmer filled her insulin prescription at a Denver-area Walgreens in January, she paid $8.50. U.S. taxpayers paid another $280.51. "It eats at me to know that taxpayer money is being wasted," said Gilmer, who has Medicare and was diagnosed with Type 1 diabetes while a sophomore at the University of Colorado in 2002. The diagnosis meant that for the rest of her life she'd require daily insulin shots to stay alive. But the price of that insulin is skyrocketing. Between 2009 and 2017 the wholesale price of a single vial of Humalog, the Eli Lilly and Co.-manufactured insulin Gilmer uses, nearly tripled — rising from $92.70 to $274.70, according to data from IBM Watson Health. Six years...
More from WN.com:
Market Exclusive 03/15/2019 14:38
To view the full exhibit click here About ELI LILLY AND COMPANY (NYSE:LLY) Eli Lilly and Company is engaged in drug manufacturing business.
More from Market Exclusive:
Healio News 03/13/2019 10:07
Lilly announces plan for generic rapid-acting insulin, teprotumumab reduces proptosis.
More from Healio News:
Pharmafile 03/13/2019 07:05
Eli Lilly’s vascular endothelial growth factor (VEGF) Receptor 2 antagonist Cyramza (ramucirumab) has succeeded in hitting its primary endpoint at Phase 3 in combination with erlotinib, the company said, as a first-line treatment in patients with ...
More from Pharmafile:
Lilly's CYRAMZA meets primary endpoint in phase 3 RELAY trial.
More from Pharmaceutical Business Review:
Benzinga 03/12/2019 12:10
Eli Lilly Could Sustain Industry-Leading Growth, Says Bullish JPMorgan (NYSE:LLY.
More from Benzinga:
ENDPOINTS 03/12/2019 10:55
Backed by OrbiMed, Lilly and now Advantech, China’s InventisBio loads up $70M to propel cancer, metabolic pipeline – Endpoints News.
More from ENDPOINTS:
pharmaphorum 03/12/2019 08:34
Eli Lilly has produced phase 3 data that supports use of its Cyramza combined with Roche’s Tarceva in first-line non-small cell lung cancer with EGFR mutations, paving the way for filings with regulators later this ...
More from pharmaphorum:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications